HOOKIPA Pharma Inc. Files 8-K for Rule 14a-12 Compliance

Ticker: HOOK · Form: 8-K · Filed: Jan 2, 2025 · CIK: 1760542

Hookipa Pharma Inc. 8-K Filing Summary
FieldDetail
CompanyHookipa Pharma Inc. (HOOK)
Form Type8-K
Filed DateJan 2, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, compliance, rule-14a-12

Related Tickers: HOOK

TL;DR

HOOKIPA (HOOK) filed an 8-K for rule 14a-12, likely related to shareholder comms.

AI Summary

HOOKIPA Pharma Inc. announced on January 2, 2025, that it is filing this Form 8-K to satisfy its reporting obligations under Rule 14a-12 of the Exchange Act. The company's common stock trades on The Nasdaq Capital Market under the symbol HOOK.

Why It Matters

This filing indicates HOOKIPA Pharma Inc. is engaging in activities that require specific SEC disclosures, potentially related to soliciting material for shareholder actions.

Risk Assessment

Risk Level: low — The filing is procedural and relates to compliance with SEC rules for communications, not a material event like an acquisition or financial distress.

Key Players & Entities

  • HOOKIPA Pharma Inc. (company) — Registrant
  • January 2, 2025 (date) — Earliest event reported
  • Rule 14a-12 (legal_document) — SEC rule for soliciting material
  • HOOK (ticker) — Trading Symbol
  • The Nasdaq Capital Market (company) — Exchange

FAQ

What is the primary purpose of this Form 8-K filing?

The primary purpose is to simultaneously satisfy the registrant's filing obligation under Rule 14a-12 of the Exchange Act, which pertains to soliciting material.

What is the earliest event date reported in this filing?

The earliest event date reported is January 2, 2025.

On which exchange is HOOKIPA Pharma Inc.'s common stock traded?

HOOKIPA Pharma Inc.'s common stock is traded on The Nasdaq Capital Market.

What is the trading symbol for HOOKIPA Pharma Inc.'s common stock?

The trading symbol for HOOKIPA Pharma Inc.'s common stock is HOOK.

Is HOOKIPA Pharma Inc. an emerging growth company?

Yes, the filing indicates that HOOKIPA Pharma Inc. is an emerging growth company.

Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2025-01-02 06:00:46

Key Financial Figures

  • $0.0001 — e on which registered Common Stock, $0.0001 par value per share HOOK The Nasdaq

Filing Documents

01 Other Information

Item 8.01 Other Information. On January 2, 2025, HOOKIPA Pharma Inc. (the "Company") and Poolbeg Pharma plc ("Poolbeg") released an announcement pursuant to Rule 2.4 of the U.K. City Code on Takeovers and Mergers that the Company and Poolbeg have entered into non-binding discussions for the potential acquisition by the Company of the entire issued share capital of Poolbeg. A copy of the announcement is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Item 8.01. The Company has prepared an investor presentation related to the proposed acquisition described above, a copy of which is attached hereto as Exhibit 99.2 and is incorporated by reference into this Item 8.01.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Announcement pursuant to Rule 2.4 of the U.K. City Code on Takeovers and Mergers, dated January 2, 2025. 99.2 Corporate Presentation, dated January 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 2, 2025 HOOKIPA Pharma Inc. By: /s/ Terry Coelho Name: Terry Coelho Title: Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.